EZH2 and hematologic disorder: Taking advantage of a previously established line of Ezh2flox/flox immortalized mouse embryonic fibroblasts (iMEFs)32, we used inducible Cre recombinase to delete Ezh2 and CRISPR/Cas9-mediated gene editing to delete Eed or introduce the H3.3K27M substitution (Supplementary Fig. 1a, b), thereby modeling mutations found in hematological malignancies, MPNST and diffuse midline glioma, respectively.